{"id":60810,"title":"Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.","abstract":"","date":"2014-06-09","categories":"Hemic and Lymphatic Diseases","split":"train","url":"http://www.ncbi.nlm.nih.gov/pubmed/24819395","annotations":[{"name":"Clinical trial","weight":0.748217,"wikipedia_article":"http://en.wikipedia.org/wiki/Clinical_trial"},{"name":"Angiogenesis","weight":0.202124,"wikipedia_article":"http://en.wikipedia.org/wiki/Angiogenesis"},{"name":"Melphalan","weight":0.196135,"wikipedia_article":"http://en.wikipedia.org/wiki/Melphalan"},{"name":"Lenalidomide","weight":0.115812,"wikipedia_article":"http://en.wikipedia.org/wiki/Lenalidomide"},{"name":"Biomarker","weight":0.0546925,"wikipedia_article":"http://en.wikipedia.org/wiki/Biomarker"},{"name":"Chronic myelomonocytic leukemia","weight":0.0400013,"wikipedia_article":"http://en.wikipedia.org/wiki/Chronic_myelomonocytic_leukemia"},{"name":"Myelodysplastic syndrome","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Myelodysplastic_syndrome"},{"name":"Drug metabolism","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Drug_metabolism"},{"name":"Risk","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Risk"},{"name":"Phase (matter)","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Phase_(matter)"},{"name":"Metronome","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Metronome"}]}
